Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 9/2019

01.09.2019 | Debate

Use of Insulin in the Inpatient Setting: Need for Continued Use

verfasst von: Smita Kumar, Mark E. Molitch

Erschienen in: Current Diabetes Reports | Ausgabe 9/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Insulin has been the standard of care for the management of inpatient diabetes for achieving strict glycemic control. This review supports continuing insulin therapy for hyperglycemic management in the hospital compared with the use of non-insulin treatment regimens.

Recent Findings

Oral hypoglycemic agents and glucagon-like peptide 1 (GLP-1) receptor agonists have typically not been used in the inpatient setting. Recent studies regarding DPP-4 inhibitors have led to variable results with fairly high glycemic values during the hospitalization. Similarly, studies looking at GLP-1 receptor agonists are limited, but gastrointestinal side effects limit their inpatient use.

Summary

Overall, there is a paucity of data to support the use of non-insulin-based therapy in the inpatient setting. Insulin has repeatedly demonstrated that its advantageous quality of being easily titratable leads to more consistently efficacious glycemic control that improves morbidity and mortality.
Literatur
1.
• Umpierrez G, Isaacs S, Bazargan N, You X, Thaler L, Kitabchi A. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978–82 This was one the first articles to stress the importance of hyperglycemia being an important contributor to inpatient mortality. CrossRef
2.
Davis G, Fayfman M, Reyes-Umpierrez D, Hafeez S, Pasquel FJ, Vellanki P, et al. Stress hyperglycemia in general surgery: why should we care? J Diab Compl. 2018;32(3):305–9.CrossRef
3.
•• Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67 This study triggered the need for better inpatient glycemic control to reduce surgical complications. CrossRef
4.
Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al. for the NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360(13):1283–1297.
5.
Preiser JC, Devos P, Ruiz-Santana S, Mélot C, Annane D, Groenveld J, et al. Prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care Med. 2009;35(10):1738–48.CrossRef
6.
Van den Berghe G, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–61.CrossRef
7.
Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults. A meta-analysis JAMA. 2008;300:933–44.PubMed
8.
Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.CrossRef
9.
American Diabetes Association. Diabetes care in the hospital. Section. 15. In Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42(Suppl. 1):S173-S181.
10.
Weintraub WS, Wenger NK, Jones EL, Craver JM, Guyton RA. Changing clinical characteristics of coronary surgery patients. Differences between men and women. Circulation. 1993;88:78–86.
11.
Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg. 1999;67:352–60.CrossRef
12.
Thourani VH, Weintraub WS, Stein B, Gebhart SSP, Craver JM, Jones EL, et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg. 1999;67:1045–52.CrossRef
13.
Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. Mayo Clin Proc. 2003;78:1471–8.CrossRef
14.
Furnary A, Wu Y, Bookin S. Effect of hyperglycemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Portland diabetic project. Endocr Pract. 2004;10:21–33.CrossRef
15.
DeSantis AJ, Schmeltz LR, Schmidt K, O’Shea-Mahler E, Rhee C, Wells A, et al. Inpatient management of hyperglycemia: the Northwestern experience. Endocr Pract. 2006;12:491–505.CrossRef
16.
Schmeltz L, DeSantis A, Thiyagarajan V, Schmidt K, O’Shea-Mahler E, Johnson D, et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. Diabetes Care. 2007;30:823–8.CrossRef
17.
Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004;109:1497–502.CrossRef
18.
Umpierrez G, Cardona S, Pasquel F, Jacobs S, Peng L, Unigwe M, et al. Randomized controlled trial of intensive versus conservative glucose control in patients undergoing coronary artery bypass graft surgery: GLUCO-CABG trial. Diabetes Care. 2015;38(9):1665–72.CrossRef
19.
Wallia A, Parikh ND, O’Shea-Mahler E, Schmidt K, DeSantis AJ, Tian L, et al. Glycemic control by a glucose management service and infection rates following liver transplantation. Endocr Pract. 2011;16:1–21.
20.
Wallia A, Schmidt K, Johnson Oakes D, Pollack T, Welsh N, Kling-Colson A, et al. Glycemic control reduces post-transplant infections in liver transplant patients: results of a prospective, randomized, study. J Clin Endocrinol Metab. 2017;102(2):451–9.PubMed
21.
Gandhi GY, Murad MH, Flynn DN, Erwin PJ, Cavalcante AB, Nielsen HB, et al. Effect of perioperative insulin infusion on surgical morbidity and mortality: systematic review and meta-analysis of randomized trials. Mayo Clin Proc. 2008;83:418–30.CrossRef
22.
• Sathya B, Davis R, Taveira T, Whitlatch H, Wu WC. Intensity of perioperative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2013;102:8–15 This recent meta-analysis confirmed the benefits of insulin-intensive therapy in reducing inpatient mortality. CrossRef
23.
Mulla I, Schmidt K, Cashy J, Wallia A, Andrei A-C, Oakes DJ, et al. Comparison of glycemic and surgical outcomes after change in glycemic targets in cardiac surgery patients. Diabetes Care. 2014;37:2960–5.CrossRef
24.
Umpierrez GE, Smiley D, Zisman A, Prieto LM, Palacio A, Ceron M, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diabetes Care. 2007;30(9):2181–6.CrossRef
25.
Umpierrez GE, Smiley D, Jacobs S, Peng L, Temponi A, Mulligan P, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34(2):256–61.CrossRef
26.
Hansen T, Thiel S, Wouters P, Christiansen J, Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab. 2003;88:1082–8.CrossRef
27.
Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest. 2004;114:1187–95.CrossRef
28.
Bakris GL, Molitch ME. Should restrictions be relaxed for metformin use in chronic kidney disease? Yes, they should be relaxed! What’s the fuss? Diabetes Care. 2016;39(7):1287–91.CrossRef
29.
Umpierrez G, Gianchandani R, Smiley D, Jacobs S, Wesorick DH, Newton C, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diabetes Care. 2013;36(11):3430–5.CrossRef
30.
Brackbill M, Rahman A, Sandy J, Stam M, Harralson A. Adjunctive sitagliptin therapy in postoperative cardiac surgery patients: a pilot study. Int J Endocrinol. 2012;2012:1–6.CrossRef
31.
Fayfman M, Davis G, Duggan EW, Urrutia M, Chachkhiani D, Schindler J, et al. Sitagliptin for prevention of stress hyperglycemia in patients without diabetes undergoing general surgery: a pilot randomized study. J Diab Compl. 2018;32(12):1091–6.CrossRef
32.
Pasquel FJ, Gianchandani R, Rubin DJ, Dungan KM, Anzola I, Gomez PC, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol. 2017;5(2):125–33.CrossRef
33.
Vellanki P, Rasouli N, Baldwin D, Alexanian S, Anzola I, Urrutia M, et al. Linagliptin Inpatient Research Group. Glycaemic efficacy and safety of linagliptin compared to basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicenter randomized clinical trial. Diabetes Obes Metab. 2018.
34.
Garg R, Schuman B, Hurwitz S, Metzger C, Bhandari S. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diabetes Res Care. 2017;5(1):e000394.CrossRef
35.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.CrossRef
36.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.CrossRef
37.
Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? Insulin therapy has proven itself and is considered the mainstay of treatment. Diabetes Care. 2013;36(7):2112–7.CrossRef
38.
Fayfman M, Galindo RJ, Rubin DJ, Mize DL, Anzola I, Urrutia MA, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diabetes Care. 2019;42(3):450–5.CrossRef
39.
Hamblin PS, Wong R, Ekinci EI, Fourlanos S, Shah S, Jones AR, et al. SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission. J Clin Endocrinol Metab. 2019.
40.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.CrossRef
41.
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J M. 2016;375(4):323–34.CrossRef
42.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.CrossRef
43.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A and the DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380(4):347–357.
44.
Lupsa BC, Inzuchhi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118–25.CrossRef
45.
Gianchandani RY, Pasquel FJ, Rubin DJ, Dungan KM, Vellanki P, Wang H, et al. The efficacy and safety of co-administration of sitagliptin with metformin in patients with type 2 diabetes at hospital discharge. Endocr Pract. 2018;24(6):556–64.CrossRef
46.
• Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41:2669–701 This consensus statement emphasized the cardiovascular and kidney benefits of GLP-1 receptor agonists and SLGT2 inhibitors in the management of patients with type 2 diabetes who have underlying cardiovascular or kidney disease. CrossRef
47.
American Diabetes Association. Pharmacologic approaches to glycemic treatment. Section. 9. In Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42(Suppl. 1):S90-S102.
Metadaten
Titel
Use of Insulin in the Inpatient Setting: Need for Continued Use
verfasst von
Smita Kumar
Mark E. Molitch
Publikationsdatum
01.09.2019
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 9/2019
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-019-1183-9

Weitere Artikel der Ausgabe 9/2019

Current Diabetes Reports 9/2019 Zur Ausgabe

Debate

Debate on Insulin vs Non-insulin Use in the Hospital Setting—Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?

Economics and Policy in Diabetes (AA Baig and N Laiteerapong, Section Editors)

Economics of Beta-Cell Replacement Therapy

Pathogenesis of Type 2 Diabetes and Insulin Resistance (M-E Patti, Section Editor)

The Beta Cell in Type 2 Diabetes

Pediatric Type 2 and Monogenic Diabetes (O Pinhas-Hamiel, Section Editor)

How Recent Advances in Genomics Improve Precision Diagnosis and Personalized Care of Maturity-Onset Diabetes of the Young

Microvascular Complications—Retinopathy (DL Chao and G Yiu, Section Editors)

Genetics of Diabetic Retinopathy

Pathogenesis of Type 1 Diabetes (A Pugliese and SJ Richardson, Section Editors)

Extracellular Vesicles in Type 1 Diabetes: Messengers and Regulators

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise